Home » Stocks » AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

Stock Price: $4.95 USD 0.10 (2.06%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $4.81 -0.14 (-2.83%) Jan 27, 6:23 AM
Market Cap 730.76M
Revenue (ttm) 1.88B
Net Income (ttm) 61.97M
Shares Out 147.56M
EPS (ttm) 0.42
PE Ratio 11.84
Forward PE 7.37
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $4.95
Previous Close $4.85
Change ($) 0.10
Change (%) 2.06%
Day's Open 4.80
Day's Range 4.80 - 5.00
Day's Volume 1,239,960
52-Week Range 2.46 - 5.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

AMRX vs. PCRX: Which Stock Is the Better Value Option?

Other stocks mentioned: PCRX
Benzinga - 2 weeks ago

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tisleliz...

Other stocks mentioned: BGNE, TTOO
Business Wire - 2 weeks ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (the “Company”) (NYSE:AMRX) and Kashiv BioSciences LLC (“Kashiv”) today announced they have entered into a definitive agreement...

Business Wire - 2 weeks ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abb...

Business Wire - 3 weeks ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal's Co-Chief Executive Officer and President, will present...

Benzinga - 1 month ago

As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from ...

Investopedia - 1 month ago

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMPH, BIIB, HZNP, PAHC, SUPN
Zacks Investment Research - 2 months ago

Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.

Business Wire - 2 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the ...

Seeking Alpha - 2 months ago

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of Amneal Pharmaceuticals (NYSE:AMRX) rose 1.0% in pre-market trading after the company reported Q3 results.

Zacks Investment Research - 2 months ago

Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the third quarter ended September 30, 2020. “Amneal delivered anot...

Zacks Investment Research - 2 months ago

Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 2 months ago

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 2 months ago

Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.

Zacks Investment Research - 3 months ago

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 3 months ago

Is (AMRX) Outperforming Other Medical Stocks This Year?

Business Wire - 3 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020...

Business Wire - 3 months ago

--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distri...

Business Wire - 3 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal’ or the “Company”) and PL Developments (PLD) today announced that they have commenced shipments of store ...

Business Wire - 4 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

Business Wire - 5 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

Seeking Alpha - 5 months ago

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Amneal (AMRX) delivered earnings and revenue surprises of 30.00% and 3.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zacks Investment Research - 5 months ago

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

In the latest trading session, Amneal Pharmaceuticals (AMRX) closed at $4.46, marking a +0.45% move from the previous day.

Zacks Investment Research - 6 months ago

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research - 6 months ago

Amneal Pharmaceuticals (AMRX) closed the most recent trading day at $4.86, moving +0.21% from the previous trading session.

Business Wire - 6 months ago

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval ...

Zacks Investment Research - 6 months ago

Amneal Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 6 months ago

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: COLL
Zacks Investment Research - 7 months ago

Amneal Pharmaceuticals, Inc. (AMRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.

Zacks Investment Research - 7 months ago

AMRX vs. COLL: Which Stock Is the Better Value Option?

Other stocks mentioned: COLL
Zacks Investment Research - 8 months ago

Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 8 months ago

Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 13% in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 10 months ago

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, MRTX, VKTX, VSTM
Zacks Investment Research - 10 months ago

Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.

Zacks Investment Research - 10 months ago

Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

The Motley Fool - 10 months ago

The company expects to produce around 20 million tablets within a month.

The Motley Fool - 10 months ago

No, but doctors can still use the drugs despite limited evidence of their effectiveness.

Other stocks mentioned: BAYRY, MYL, NVS, TEVA
The Motley Fool - 10 months ago

The online pharmacy conducted its own tests of the type-2 diabetes drug and found excessive levels of a carcinogenic compound in 42% of the batches it tested.

Seeking Alpha - 11 months ago

Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Amneal (AMRX) delivered earnings and revenue surprises of 60.00% and 3.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

About AMRX

Amneal Pharmaceuticals, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manuf... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2002
CEO
Chirag K. Patel
Employees
5,500
Stock Exchange
NYSE
Ticker Symbol
AMRX
Full Company Profile

Financial Performance

In 2019, AMRX's revenue was $1.63 billion, a decrease of -2.20% compared to the previous year's $1.66 billion. Losses were -$361.92 million, 1,630.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for AMRX stock is "Hold." The 12-month stock price forecast is 4.83, which is a decrease of -2.42% from the latest price.

Price Target
$4.83
(-2.42% downside)
Analyst Consensus: Hold